Results 71 to 80 of about 1,029,181 (225)

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Effects of hallucinogenic drugs on the human heart

Frontiers in Pharmacology
Hallucinogenic drugs are used because they have effects on the central nervous system. Their hallucinogenic effects probably occur via stimulation of serotonin receptors, namely, 5-HT2A-serotonin receptors in the brain.
Joachim Neumann, Stefan Dhein, Uwe Kirchhefer, Britt Hofmann, Ulrich Gergs   +4 more
doaj   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample

Frontiers in Psychiatry, 2023
ObjectiveIn recent years, there has been a renewed interest in investigating the use of classic psychedelics such as psilocybin and lysergic acid diethylamide (LSD) in the treatment of mental disorders and substance use disorders.
Tor-Morten Kvam, Tor-Morten Kvam, Malin V. Uthaug, Malin V. Uthaug, Malin V. Uthaug, Kristoffer A. A. Andersen, Kristoffer A. A. Andersen, Birk Berggrav Refsum, Paula Aarseth Tunstad, Lowan Han Stewart, Henrik Børsting Jacobsen, Henrik Børsting Jacobsen, Cato Grønnerød   +12 more
doaj   +1 more source

Hallucinogen Rating Scale (HRS) - A Brazilian version: translation and cross-cultural adaptation [PDF]

, 2011
BACKGROUND: There is a growing scientific interest in the effects of hallucinogens in general and the religious use of psychoactive brew ayahuasca in Brazil in particular.
Barbosa, Paulo César Ribeiro, Mizumoto, Suely, Silveira, Dartiu Xavier da, Strassman, Rick J.   +3 more
core   +3 more sources

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Mismatch negativity generation in the human 5HT agonist and NMDA antagonist model of psychosis [PDF]

, 2008
RATIONALE: Many studies have reported deficits of mismatch negativity (MMN) in schizophrenic patients. Pharmacological challenges with hallucinogens in healthy humans are used as models for psychotic states.
Karsten Heekeren, Jörg Daumann, Anna Neukirch, Carsten Stock, Wolfram Kawohl, Christine Norra, Till D. Waberski, Euphrosyne Gouzoulis-Mayfrank, WM Abi-Saab, K Alho, T Baldeweg, SV Catts, JD Cohen, E Gouzoulis-Mayfrank, E Gouzoulis-Mayfrank, K Heekeren, DC Javitt, DC Javitt, G Juckel, S Kahkonen, I Kreitschmann-Andermahr, I Kreitschmann-Andermahr, S Leung, GA Light, GA Light, PT Michie, R Naatanen, R Naatanen, R Naatanen, B Oranje, E Pekkonen, A Pfefferbaum, TW Picton, T Rinne, W Ritter, T Rosburg, DF Salisbury, H Tiitinen, J Todd, D Umbricht, D Umbricht, D Umbricht, D Umbricht, DS Umbricht, FX Vollenweider, TD Waberski, G Winterer   +46 more
core   +2 more sources

Changes over time in hallucinogen‐related emergency department visits in Ontario, Canada

Addiction, EarlyView.
Abstract Background and aims Recent increasing interest in hallucinogens has underscored the critical gaps in our understanding of their adverse health effects and healthcare usage over time. The current study aimed to examine changes in emergency department (ED) visit rates involving hallucinogens, clinical outcomes of visits and the characteristics ...
Daniel T. Myran, Rachael MacDonald‐Spracklin, Alexander R. Levesque, Michael Pugliese, Jess G. Fiedorowicz, André J. McDonald, Joshua D. Rosenblat, Ian Colman, Josephine Zein, Marco Solmi   +9 more
wiley   +1 more source

Updated View on the Relation of the Pineal Gland to Autism Spectrum Disorders

Frontiers in Endocrinology, 2019
Identification of the biological features of autism is essential for designing an efficient treatment and for prevention of the disorder. Though the subject of extensive research, the neurophysiological features of autism remain unclear.
Tal Shomrat, Nir Nesher
doaj   +1 more source

Targeting INMT and interrupting its methylation pathway for the treatment of castration resistant prostate cancer

Journal of Experimental & Clinical Cancer Research, 2021
Background Castration-resistant prostate cancer (CRPC) is associated with a very poor prognosis, and the treatment of which remains a serious clinical challenge.
Shangwei Zhong, Ji-Hak Jeong, Changhao Huang, Xueyan Chen, Shohreh Iravani Dickinson, Jasreman Dhillon, Li Yang, Jun-Li Luo   +7 more
doaj   +1 more source